The University at Buffalo School of Pharmacy and Pharmaceutical Sciences has its own resident expert in the fields of ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

A US Safety Review Committee (SRC) has granted unanimous approval for TransCode Therapeutics to open the fourth cohort in its ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

today announced the positive results from the Company's pilot nonclinical pharmacokinetic (PK) study for its new generation levodopa/carbidopa asset for Parkinson's disease (PD), LXM.5. The ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported ...